Botulinum Toxin: A Complete Guide to Anti-Wrinkle Treatment, Nefertiti Neck Lift, and Hyperhidrosis

Botulinum toxin type A is one of the most familiar names in aesthetic medicine, yet it is also one of the easiest treatments to oversimplify. Some people imagine that every treatment should remove all movement. Others assume that because the injections are quick, the clinical decision is simple. Neither description is accurate.

The medicine works by temporarily reducing signalling between nerves and selected muscles or, in some medical indications, between nerves and sweat glands. What matters clinically is not simply whether the medicine can relax tissue, but which structure is being targeted, why, how much effect is appropriate and whether the proposed use is licensed for the specific product being considered.

This guide is deliberately educational rather than promotional. Botulinum toxin type A is a prescription-only medicine in the UK. Different licensed products have different indications, dosing units and prescribing information, and their units are not interchangeable. Suitability can only be decided after an appropriate clinical assessment by a prescriber.

There are two opposite myths around prescription wrinkle treatments. The first is that a successful treatment should make the face completely still. The second is that the procedure is so routine that the person holding the syringe matters very little. In reality, the medicine is predictable only when anatomy, dose, product characteristics and the patient’s baseline movement are all considered together.

Facial muscles do not work in isolation. The forehead, brow depressors, muscles around the eyes and lower-face muscles pull in different directions and often counterbalance one another. Reducing one muscle too strongly can therefore change the way another part of the face moves. This is why an apparently simple request such as “soften my forehead” cannot be planned safely from a photograph or a fixed number of injection points.

At the neuromuscular junction, nerves normally release acetylcholine to signal a muscle to contract. Botulinum toxin type A interferes with that release. The result is a temporary reduction in the activity of the injected muscle. In sweat glands, the same cholinergic signalling pathway is used differently: reducing acetylcholine release can decrease local sweat production.

This mechanism explains both the usefulness and the limits of the medicine. It can reduce a specific signal, but it does not replace lost facial volume, remove excess skin or correct every type of wrinkle. It also does not create a permanent change: nerve terminals recover over time and activity returns.

One of the most useful distinctions in consultation is the difference between a line that appears mainly with movement and a line that remains visible when the face is at rest. The first is driven more directly by repeated muscle contraction. The second may also reflect skin ageing, collagen and elastin change, sun exposure, tissue quality and sometimes volume loss.

This is also why prevention claims need care. Reducing repeated contraction may reduce how strongly some dynamic lines are expressed while treatment is active, but it should not be presented as a guarantee that ageing or permanent lines can be prevented.

The upper face is where most patients first encounter prescription wrinkle treatment: the glabellar region between the brows, lateral canthal lines around the eyes and horizontal forehead lines. Some currently licensed UK products include one or more of these indications, but the exact licensed areas vary by product.

Natural-looking treatment is not simply a matter of leaving “some movement”. The clinician must understand which muscles elevate the brow, which depress it and how much activity the patient uses when speaking, smiling or concentrating. A person with a naturally low brow, for example, may rely heavily on the frontalis muscle to keep the brow elevated. Reducing that muscle too aggressively can create heaviness rather than freshness.

The same principle applies around the eyes. Softening lateral movement may change the appearance of crow’s-feet, but treatment must be planned around eyelid support, brow position and smile dynamics. The aim should be a clinically appropriate effect, not a frozen face.

The term “Nefertiti neck lift” is a marketing label rather than a surgical operation. The anatomical conversation is about the platysma: a broad, thin muscle that extends from the upper chest and neck into the lower face. When it contracts, some fibres can create visible vertical bands and downward pull in the lower face and neck.

The UK licensing picture has evolved. At least one currently licensed botulinum toxin type A product includes temporary improvement of moderate-to-severe platysma prominence seen at maximum contraction in adults when the severity has an important psychological impact. That does not mean that every neck or jawline injection marketed under a “Nefertiti” label is automatically the same licensed use. The status depends on the exact product, indication and injection plan.

Hyperhidrosis is excessive sweating that is disproportionate to the body’s normal need for temperature regulation. When it affects the underarms, the clinical discussion is different from facial aesthetics even though the medicine may act through the same neurotransmitter pathway.

Some botulinum toxin type A products have a licensed indication for severe primary axillary hyperhidrosis that has not responded adequately to topical treatment. In this setting the medicine is injected within the skin of the axillary area to reduce cholinergic stimulation of sweat glands. Improvement is temporary and repeat treatment may be considered when the effect diminishes, subject to the prescribing information and individual assessment.

Excessive sweating can also have secondary causes. A careful history matters because a change in sweating pattern, generalised sweating or symptoms such as weight change, palpitations, fever or night sweats may need medical investigation rather than simply local treatment.

Patients often hear a long list of terms online: brow lift, lip flip, gummy smile, masseter reduction, jaw slimming, chin dimpling and other targeted injection patterns. It is important to separate internet terminology from medicine licensing. A use can be clinically familiar and still be off-label for the particular medicine being considered.

Licensed indications differ between products. If a clinician recommends an off-label use, that should form part of informed consent: the patient should understand that the medicine is being used outside the terms of its marketing authorisation for that specific purpose, why it is being considered and what alternatives exist.

This distinction is especially important on clinic websites. UK CAP guidance says information about prescription-only medicines on inner website pages should be balanced and factual, should reflect the product information and should not promote unlicensed indications as though they were licensed treatment claims.

The consultation is not a formality before the injections. It is where the clinical decision is made. For doctors, GMC guidance requires a physical examination before prescribing injectable cosmetic medicines; they must not be prescribed remotely without examining the patient.

A responsible plan moves through a series of decisions rather than beginning with a syringe. The exact pathway varies by indication, but the logic is consistent: identify the problem, confirm that the medicine is appropriate, establish what is licensed for the chosen product, agree the intended degree of effect and only then decide dose and placement.

The practical part of treatment is usually short compared with the assessment that should come before it. The skin is examined and cleaned, the planned injection sites are identified and small volumes are delivered using a fine needle. The number of injection points depends on the indication, the medicine and the individual plan; there is no single injection count that applies to every patient.

Brief stinging, pressure, small raised areas, pinpoint redness or minor bruising can occur at injection sites. Topical anaesthetic is not always necessary, but comfort measures may be discussed depending on the treatment area and patient preference.

For hyperhidrosis, injection points are distributed across the affected underarm area rather than into one facial muscle. The technique and depth are therefore different even though the active medicine may be from the same therapeutic class.

Most patients can return to ordinary activities quickly, but “no downtime” is too absolute. Redness, small bumps, tenderness, bruising or headache can occur, and the relevance of these effects varies from person to person.

Aftercare advice should be based on the product information and the clinician’s own protocol. Some traditional instructions — such as remaining upright for a fixed number of hours or avoiding all exercise — are commonly given, but they should not be presented as universal scientific certainties when evidence is limited. The more important message is to avoid unnecessary pressure or manipulation of the treated area immediately after injection and to follow the specific instructions provided by the treating clinician.

• Do not stop prescribed anticoagulants or other medicines solely to reduce bruising unless the clinician who manages that medicine advises it.
• If bruising occurs, it is usually local and temporary, but patients should seek advice if swelling, pain or other symptoms are unexpectedly severe.
• If the treatment involves the underarms, local tenderness or bruising can occur and the area should be kept clean according to the clinician’s instructions.
• If a patient develops symptoms that suggest a more significant reaction, ordinary aftercare advice is no longer enough and medical assessment is needed.

Botulinum toxin does not create an instant final result. The onset depends on the medicine and indication, but changes typically develop over several days and continue to evolve before a stable effect can be judged. Product information for different licensed medicines reports different onset and duration profiles, which is another reason not to treat every product as interchangeable.

In facial-line indications, the effect is temporary and commonly measured in months rather than years. For licensed axillary hyperhidrosis treatment, some product information describes benefit lasting several months as well. The exact duration depends on product, indication, dose, muscle or gland activity and individual response.

Most reported adverse effects are local and temporary, but the risk profile depends on where the medicine is injected. Because the effect is based on reducing nerve signalling, unwanted weakness in a nearby muscle is a predictable type of complication when toxin activity spreads beyond the intended target.

Contraindications and precautions differ between products, so the specific Summary of Product Characteristics and patient information leaflet matter. Common themes include avoiding injection when there is infection at the proposed site and taking particular care in patients with certain neuromuscular disorders or medicines that can affect neuromuscular transmission.

Pregnancy and breastfeeding are also important. Cosmetic use is generally avoided because safety data are limited, but wording differs between products. It is more accurate to say that treatment is usually not recommended in these circumstances than to describe pregnancy or breastfeeding as a universal “absolute contraindication” for every product.

Treatment may also need to be postponed if the clinical goal is unclear, if there has been a significant recent adverse reaction, if the patient expects a permanent result or if the concern is mainly caused by skin excess, volume loss or another anatomical issue that the medicine cannot reasonably address.

Botulinum toxin type A has a substantial evidence base across both therapeutic and cosmetic indications, but evidence is product- and indication-specific. The correct question is not simply “does botulinum toxin work?” but whether the chosen licensed product has evidence and authorisation for the particular indication being discussed, and whether the proposed use is suitable for the individual patient.

The UK regulatory context also changes how clinics should communicate about these medicines. Prescription-only medicines cannot be advertised directly to the public. CAP guidance allows only narrow, factual references on deeper website pages, presented as a possible outcome of a consultation rather than as a product being promoted. Public advertising should focus on consultation for the concern, not on selling the prescription medicine.

For doctors, GMC guidance requires a physical examination before prescribing injectable cosmetic medicines. That means the prescription decision cannot be made purely by telephone, video or an online form. Consent, treatment planning and responsibility for follow-up should all reflect the fact that this is a prescription intervention rather than a retail cosmetic product.

These answers are intentionally general. The exact medicine, indication, dose, aftercare and follow-up plan should come from the prescriber and the relevant product information.

Related treatment: Anti-wrinkle & targeted injections